



Cite this: *Biomater. Sci.*, 2018, **6**, 2101

## Antibiotic functionalised polymers reduce bacterial biofilm and bioburden in a simulated infection of the cornea†

Natalya Doroshenko,<sup>a</sup> Stephen Rimmer,<sup>b</sup> Richard Hoskins,<sup>b</sup> Prashant Garg,<sup>c</sup> Thomas Swift,<sup>b</sup> Hannah L. M. Spencer,<sup>b</sup> Rianne M. Lord,<sup>b</sup> Maria Katsikogianni,<sup>b</sup> David Pownall,<sup>b</sup> Sheila MacNeil,<sup>d</sup> C. W. Ian Douglas<sup>a</sup> and Joanna Shepherd<sup>\*,a</sup>

Microbial keratitis can arise from penetrating injuries to the cornea. Corneal trauma promotes bacterial attachment and biofilm growth, which decrease the effectiveness of antimicrobials against microbial keratitis. Improved therapeutic efficacy can be achieved by reducing microbial burden prior to antimicrobial therapy. This paper assesses a highly-branched poly(*N*-isopropyl acrylamide) with vancomycin end groups (HB-PNIPAM-van), for reducing bacterial attachment and biofilm formation. The polymer lacked antimicrobial activity against *Staphylococcus aureus*, but significantly inhibited biofilm formation ( $p = 0.0008$ ) on plastic. Furthermore, pre-incubation of *S. aureus* cells with HB-PNIPAM-van reduced cell attachment by 50% and application of HB-PNIPAM-van to infected *ex vivo* rabbit corneas caused a 1-log reduction in bacterial recovery, compared to controls ( $p = 0.002$ ). In conclusion, HB-PNIPAM-van may be a useful adjunct to antimicrobial therapy in the treatment of corneal infections.

Received 17th February 2018,  
Accepted 17th May 2018

DOI: 10.1039/c8bm00201k

rsc.li/biomaterials-science

### Introduction

Biofilm formation is central to the colonisation of materials and tissues by infective bacteria.<sup>1</sup> The adhesion of bacterial cells to surfaces (whether biotic or abiotic) is the initial stage of formation of biofilms,<sup>2</sup> which are bacterial communities attached to a surface encased in a biopolymer matrix.<sup>3</sup> It is estimated that 80% of all clinical infections are biofilm related<sup>4</sup> and the particular clinical problem they pose is their high levels of antimicrobial non-responsiveness compared with planktonic bacteria. This non-responsiveness is not generally due to acquisition of resistance genes but instead arises from altered physiological and physical features of the community.<sup>5,6</sup> The biomolecule-enriched matrix provides a penetration barrier to antimicrobials<sup>7</sup> and subpopulations of bacteria in biofilms (known as persister cells) grow more slowly and are less metabolically active than their planktonic

counterparts.<sup>5</sup> Thus biofilm infections are difficult to treat and therefore strategies that prevent biofilm formation or disrupt established biofilms may offer valuable adjuncts to antimicrobial therapy.<sup>8–10</sup> Biofilm disruption can be achieved by applying complexing agents or surfactant molecules,<sup>11–13</sup> such as low molar mass<sup>14</sup> or polymer amphiphiles.<sup>15,16</sup> Antimicrobial peptides and lipopeptides are also amphiphiles and they are known to disrupt biofilms.<sup>17,18</sup>

In previous work we showed that highly-branched poly(*N*-isopropyl acrylamide) (HB-PNIPAM) functionalised at the chain ends with vancomycin (HB-PNIPAM-van) responded after binding to bacteria by desolvation of a fraction of the polymer segments.<sup>19–22</sup> Upon attachment of bacteria to the vancomycin chain ends, the polymer passes through a phase transition that involves desolvation of segments. This induces a change in the conformation of the polymer from a coiled to a globular state (Fig. 1), which in this context manifests macroscopically as the formation of polymer–bacteria aggregates. Similarly, results were reported with a polymyxin variant of the same polymers (HB-PNIPAM-pmx) on binding to the Gram negative species, *Pseudomonas aeruginosa*.<sup>23</sup> Although often described as a hydrophobic phase, the globular desolvated state is amphiphilic and retains water after the main desolvation event. In this context, we considered that bacteria being bound within the desolvated polymer structures would disrupt biofilms in the same way that other amphiphiles have been shown to act. However, the disruptive action would be

<sup>a</sup>School of Clinical Dentistry, University of Sheffield, Sheffield, S10 2TA, UK.  
E-mail: j.shepherd@sheffield.ac.uk


<sup>b</sup>Department of Chemistry and Biosciences, University of Bradford, Bradford, BD7 1DP, UK

<sup>c</sup>Kallam Anji Reddy Campus, L V Prasad Marg, Banjara Hills, Hyderabad 500 034, Telangana, India

<sup>d</sup>Department of Materials Science and Engineering, University of Sheffield, Sheffield, S3 7HQ, UK

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c8bm00201k





**Fig. 1** Diagram showing the interaction of HB-PNIPAM-van with Gram-positive bacteria. (a) Chain-end groups bind to bacteria, causing the outer segments in HB-PNIPAM-van to desolvate (shown in black), providing an interface that promotes adhesion of bacteria more effectively than the solvated state. (b) Solvated state of HB-PNIPAM-van (shown in blue) does not promote bacterial binding.

expected to be enhanced as the polymer competes with the extracellular macromolecules of the biofilm to bind to the resident bacteria. In support of this concept, previous work by us has also shown that both HB-PNIPAM-van and HB-PNIPAM-pmx can dislodge bacteria from *in vitro* infected dermal tissue models.<sup>20</sup>

As an exemplar of this principle we examined the effect of the HB-PNIPAM-van polymer on biofilms associated with infection of the eye, microbial keratitis. Microbial keratitis is a


sight-threatening disease, and is recognized by the World Health Organization as a major cause of corneal-related blindness.<sup>24</sup> The disease can have a bacterial, fungal, viral or protozoal cause and the most common bacteria are *Staphylococcus aureus* and *Pseudomonas aeruginosa*,<sup>25</sup> although streptococcal and enterobacterial causes are also known. Since ophthalmic biofilm infections, also implicated in cases of endophthalmitis and crystalline keratopathy,<sup>26</sup> are so difficult to treat, surgical removal of the infected tissue resulting in corneal blindness often remains the only permanent treatment option.<sup>27</sup>

In this work, we evaluate the effect of HB-PNIPAM-van on the ability of *S. aureus* to attach and form a biofilm on a plastic substrate and its ability to remove bacteria from a simulated infection model of keratitis using *ex vivo* rabbit corneas.

## Results and discussion

### HB-PNIPAM-van binds *S. aureus* but not *P. aeruginosa*

A HB-PNIPAM-van polymer was prepared. The material had a degree of branching of 0.042,  $M_n$  1937 kDa,  $M_w$  = 2269 kDa, and the chain end functionality was 0.08 mg vanc per mg polymer, (see ESI† for full details). HB-PNIPAM-van has been previously shown to interact with *S. aureus* using an “aggregation assay” that showed the formation of large bacterial aggregates in the presence of HB-PNIPAM-van.<sup>19,20</sup> In the work reported here, electron microscopy was used to investigate the polymer–bacteria interaction. Fig. 2a shows an image of *S. aureus* alone dispersed evenly on a surface. Incubation of



**Fig. 2** Incubation of *S. aureus* with HB-PNIPAM-van results in formation of aggregates. (a) Electron micrographs showing the formation of *S. aureus* and HB-PNIPAM-van aggregates. Scale bar, 20  $\mu$ m. More images of polymer–bacteria aggregates can be seen in ESI, Fig. S5 and S6.† (b) The average number of viable *S. aureus* and *P. aeruginosa* cells attached to HB-PNIPAM-van-treated or PBS-treated (control) microplate wells. Error bars; standard error of the mean,  $n = 9$  (3 independent experiments, 3 replicates for each experiment).



HB-PNIPAM-van with *S. aureus* for 4 hours resulted in the formation of large bacterial aggregates with average dimensions of 13  $\mu\text{m}$ . Further images of aggregates formed by HB-PNIPAM-van only and HB-PNIPAM-van with *S. aureus* over shorter timescales can be seen in ESI, Fig. S5 and S6.†

To quantify the degree of polymer–bacteria interaction, viable counts of attached bacteria in wells to which HB-PNIPAM-van was anchored to the surface *via* an anti-vancomycin antibody were determined. For comparison attachment of a Gram-negative species, *P. aeruginosa*, which should not bind significantly to HB-PNIPAM-van, was assessed. The value for *S. aureus* attachment to the control wells (anti-vancomycin but no polymer) was higher than expected but this was probably due to protein A-mediated binding to the mouse IgM. Nonetheless, viable count data showed a significant, 60% rise in *S. aureus* cell attachment ( $p = 0.0038$ ) to polymer-coated wells as opposed to the uncoated control (PBS) (Fig. 2b). Moreover, there was no significant difference in the attachment of *P. aeruginosa* to PBS or HB-PNIPAM-van treated surfaces, confirming earlier findings that HB-PNIPAM-van exhibits binding specificity for *S. aureus*.<sup>20</sup>

### HB-PNIPAM-van inhibits cell attachment and biofilm formation


To determine the effect of HB-PNIPAM-van on *S. aureus* biofilm formation, total biofilm biomass of 24 h biofilms formed in the presence of HB-PNIPAM-van was measured using crystal violet staining. HB-PNIPAM-van caused a 38% and 61% reduction in biofilm biomass formed by *S. aureus* S-235 and *S. aureus* NCTC 8325-4 respectively, when compared to the PBS control (Fig. 3). It is important to highlight that the concentration of HB-PNIPAM-van used in this assay was 10 times lower ( $0.5 \text{ mg ml}^{-1}$ ) than in the other experiments presented in this paper but was still sufficient to cause a statistically significant inhibition of biofilm formation for *S. aureus* S-235 ( $p = 0.0008$ ) and *S. aureus* NCTC 8325-4 ( $p = 0.001$ ). Interestingly, HB-PNIPAM-van caused a larger reduction in the

biofilm biomass of *S. aureus* NCTC 8325-4, which was the better biofilm-forming strain.


To determine how HB-PNIPAM-van interferes with biofilm formation, Syto9-stained *S. aureus* S-235 was pre-incubated with HB-PNIPAM-van and added to a microplate to initiate attachment. The results showed that a much lower proportion of *S. aureus* attached to the micro-plate when the bacteria were pre-treated with HB-PNIPAM-van as opposed to treatment with PBS (Fig. 4a). Furthermore, the micrographs were confirmed by quantification of fluorescence intensity of attached bacteria, which showed that polymer pre-treated cells attached at a statistically significantly lower level than untreated cells ( $p < 0.001$ ) (Fig. 4b). A similar experiment in which the fluorescence intensity of different concentrations of *S. aureus* (cells per ml) was measured (ESI, Fig. S7†) revealed that  $10^9$  cells per ml resulted in a fluorescence intensity reading of 43 687 RFU. The difference in fluorescence intensity from the bacterial cells treated with PBS or HB-PNIPAM-van treated surfaces was 12 583 RFU (Fig. 4b). This suggests that HB-PNIPAM-van inhibited the attachment of approximately  $3 \times 10^8$  cells per ml.

### HB-PNIPAM-van changes biofilm architecture

To assess the effects of HB-PNIPAM-van on pre-formed biofilms, the total number of bacteria left after treatment with HB-PNIPAM-van and their metabolic activity was quantified from biofilms treated with PBS or HB-PNIPAM-van for 24 hours. The results showed no significant differences in the




**Fig. 3** HB-PNIPAM-van inhibits *S. aureus* biofilm formation. Total biofilm biomass measured by absorbance of crystal violet of 24 h *S. aureus*, S235 and *S. aureus* NCTC 8325-4 biofilms, grown in microplate wells in BHI or BHI supplemented with  $500 \mu\text{g ml}^{-1}$  of HB-PNIPAM-van. Error bars; standard error of the mean,  $n = 18$  (3 independent experiments, 6 replicates for each experiment).




**Fig. 4** HB-PNIPAM-van inhibits *S. aureus* attachment. (a) Fluorescence microscopy images of *S. aureus* cells stained with Syto-9 attached to microplate wells following a 4 h, pre-incubation period with HB-PNIPAM-van or PBS (control). Images are representative of data from 3 independent experiments. (b) Fluorescence intensity of *S. aureus* cells attached to microplate wells following a 4 h, pre-incubation period with HB-PNIPAM-van or PBS (control). Error bars; error of the mean,  $n = 18$  (3 independent experiments, 6 replicates for each experiment).



number of recovered viable bacteria from biofilms treated with PBS ( $2.7 \times 10^8 (\pm 6.7 \times 10^7)$  CFU ml<sup>-1</sup>) or HB-PNIPAM-van ( $2.8 \times 10^8 (\pm 3.9 \times 10^7)$  CFU ml<sup>-1</sup>) (Fig. 5a), indicating that HB-PNIPAM-van did not kill bacteria in this system. Similarly, there was no difference in the metabolic activity of bacteria between the PBS and HB-PNIPAM-van treated biofilms (Fig. 5b) suggesting that HB-PNIPAM-van has no effect on proliferation of bacteria within biofilms. However when PBS and polymer-treated biofilms were analysed by microscopy, differences in the structure of the biofilm were observed (Fig. 6). Phase contrast microscopy showed that compared to biofilms exposed to HB-PNIPAM-van, PBS-treated biofilms were formed of larger aggregates (Fig. 6a). Similarly, SEM data revealed that control biofilms contained fewer but larger aggregates than the polymer-treated biofilm (Fig. 6b). High magnification images of the aggregates observed in both biofilm samples also showed that control biofilms consisted of much larger aggregates (Fig. 6c). Since the bacterial population between PBS-treated and polymer-treated biofilms is similar (Fig. 5a), it is possible that bacteria residing in control biofilms produce a greater abundance of biofilm matrix molecules which form the basis of the larger aggregates observed in control biofilms.



**Fig. 5** HB-PNIPAM-van does not affect biofilm bacterial growth. (a) The number of bacterial cells recovered from 24 h biofilms of *S. aureus* following 24 h treatment with PBS or HB-PNIPAM-van ( $5 \text{ mg ml}^{-1}$ ). Error bars; standard error of the mean,  $n = 9$  (3 independent experiments, 3 replicate biofilms for each experiment). (b) Absorbance of XTT solution converted by metabolically active bacterial cells from PBS and HB-PNIPAM-van treated *S. aureus* biofilms. Error bars; standard error of the mean,  $n = 15$  (3 independent experiments, 5 replicate biofilms for each experiment).



**Fig. 6** HB-PNIPAM-van changes biofilm structure. Representative microscopy images of *S. aureus* 24 h biofilms following treatment with PBS (control) or HB-PNIPAM-van for 24 hours; (a) phase contrast-microscopic images of control and HB-PNIPAM-van-treated biofilms, (b) low magnification electron microscopic image of similar samples stained with alcian blue and osmium tetroxide. (c) High magnification electron microscopic images of samples in (b). (d) Fluorescence microscopic images of treated and untreated biofilms stained with Texas Red wheat germ agglutinin (WGA). White arrows indicate aggregates.


Given that HB-PNIPAM-van binds bacteria, the findings presented in Fig. 6c, suggest that the polymer may have prevented *S. aureus* cells from either being integrated into the already formed aggregates or from actively forming their own aggregates, and so HB-PNIPAM-van may promote the segregation of *S. aureus* as individual cells (Fig. 6c).

Data from fluorescence experiments, in which PBS and polymer-treated biofilms were stained with the fluorescently labelled lectin (WGA), showed that polymer-treated biofilms appeared thinner and more dispersed compared to control biofilms, which developed as a thick collection of conjoined aggregates (Fig. 6d). Since poly-*N*-acetylglucosamine (PNAG) is an abundant component of *S. aureus* biofilms and WGA binds to *N*-acetylglucosamine residues within bacteria and the biofilm matrix, the data suggest that the abundance of PNAG was reduced in the biofilm exposed to HB-PNIPAM-van, given the absence of larger areas of WGA fluorescence (Fig. 6d). Collectively these findings imply that HB-PNIPAM-van alters the biofilm structure and possibly the arrangement of bacteria within the biofilm.



## HB-PNIPAM-van reduces the bioburden in a corneal infection model

To test the potential of HB-PNIPAM-van as a treatment for tissue infections, HB-PNIPAM-van or PBS (control treatment) were applied to deliberately wounded and infected *ex vivo* rabbit corneas for a period of 4 hours. Afterwards the corneas were washed and the remaining bacteria enumerated. The data showed that corneas exposed to HB-PNIPAM-van contained significantly fewer ( $p < 0.002$ ) bacteria than corneas treated with PBS (Fig. 7a). Since the application of HB-PNIPAM-van to infected corneas resulted in a 10-fold reduction in concentration (CFU ml<sup>-1</sup>) of bacteria, this demonstrates that HB-PNIPAM-van effectively reduces the bioburden in a corneal infection.



**Fig. 7** HB-PNIPAM-van reduces bacterial load in a corneal infection model. (a) The number of *S. aureus* cells recovered from *S. aureus* infected *ex vivo* rabbit corneas following a 4 h treatment with HB-PNIPAM-van or PBS (control). Error bars; standard error of the mean,  $n = 9$  (3 independent experiments, 3 replicate corneas per an experiment). (b) Photograph of an *ex vivo* rabbit cornea which has been scratched with several criss-cross lines using a scalpel. Scratches are illustrated in the photograph with black solid lines. The box drawn in black dashed lines represents areas of interest which formed the basis of confocal microscopy analysis; *i.e.* the scratch sites were predicted to harbour most bacteria and so confocal images of these particular sites of the cornea were taken. (c) Representative confocal microscopy images of infected *ex vivo* rabbit corneas following a 4 h treatment with HB-PNIPAM-van or PBS (control). White dashed outline illustrates the shape of the scratch made during the infection stage of the experiment. Background fluorescence is auto-fluorescence from the cornea. White arrows indicate bright circular aggregates of GFP-labelled *S. aureus*, which are confined to the scratch area. Raw confocal microscopy images can be seen in ESI, Fig. S4.†

In a similar experiment, PBS and polymer-treated corneas were examined by microscopy, specifically focusing on the area around the wound made to the cornea during the infection process, as this was the area of the cornea previously shown to harbour the most bacteria.<sup>28</sup> As seen in Fig. 7b & c, in the PBS-treated cornea, GFP-labelled *S. aureus* formed large aggregates not only in the location of the wound, but throughout the entire cornea. Alternatively, the cornea exposed to HB-PNIPAM-van treatment appeared to contain much fewer *S. aureus* aggregates and these appeared smaller in size and were mostly localised around the surface of the scratch wound (Fig. 7b & c). Some green background autofluorescence from the corneal cells is also visible.

To address any potential cytotoxicity issues, all polymeric materials were found to be non-toxic to human epithelial (and other tested) cell types following 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) cell viability tests (see ESI, Table S3†).

## Discussion

The aim of this study was to explore the potential of HB-PNIPAM-van to influence biofilm formation and already formed biofilms both on abiotic surfaces and in an infected tissue model. This study builds on the work of Shepherd *et al.* (2011),<sup>20</sup> which showed that HB-PNIPAM-van could bind but not kill bacteria in an infected skin wound model and shows the generality of the approach. The findings presented here provide more information on how the HB-PNIPAM-van interacts with *S. aureus* and how the polymer affects the formation and development of *S. aureus* biofilms.

The current work shows that HB-PNIPAM-van exhibited activity against *S. aureus* but not *P. aeruginosa* (Fig. 2b), which is consistent with the binding mechanism of vancomycin; the Gram-negative outer membrane provides a penetration barrier to large molecules like vancomycin<sup>29</sup> and HB-PNIPAM-van, so preventing binding to the vancomycin target. Furthermore, effective binding between HB-PNIPAM-van and *S. aureus* (an interaction which caused a significant reduction in bacterial numbers in infected cornea, Fig. 7) occurred within a relatively short time frame (4 hours), suggesting that HB-PNIPAM-van could be a viable candidate for topical application. Using a tissue-engineered human skin model of a burn wound, it was previously shown that treatment with HB-PNIPAM-van for 1 hour caused a significant reduction of the bacterial bioburden in the wound,<sup>20</sup> thus further demonstrating the versatility of this polymer. Biofilm formation of *S. aureus* in nutrient rich media was inhibited in the presence of HB-PNIPAM-van (Fig. 3) and pre-incubation of *S. aureus* cells with HB-PNIPAM-van inhibited their attachment to an abiotic surface (Fig. 4). Many bacteria live on surfaces as biofilms; contact lens-associated microbial keratitis is characterized by biofilm growth on the lens, whereas in endophthalmitis, staphylococci adhere to intraocular lenses leading to infection of the intraocular cavity.<sup>26</sup> Treatment with HB-PNIPAM-van may be of benefit in such cases as the anti-fouling properties of HB-PNIPAM-van may prevent the bacteria on the implant from spreading,



attaching and colonizing the cornea and thus HB-PNIPAM-van may retard the development of implant associated corneal infections. However, this requires further exploration.

Important findings from this study show that HB-PNIPAM-van is able to reduce the binding of bacteria to surfaces and alter the structure of the remaining biofilm (Fig. 6) in an established corneal infection (Fig. 7) Compared to a biofilm treated with PBS, HB-PNIPAM-van treated biofilms consisted of smaller bacterial aggregates and a more dispersed biofilm matrix showed that HB-PNIPAM-van is able to bind bacteria from an established corneal infection (Fig. 7), and that it altered the structure of the remaining biofilm (Fig. 6). Compared to a biofilm treated with PBS, HB-PNIPAM-van treated biofilms consisted of smaller bacterial aggregates. Such modified biofilm structures may allow greater penetration of antimicrobials into the depths of the biofilm and achieve greater killing. Collectively these data suggest that HB-PNIPAM-van could be given as an adjunctive topical treatment alongside antimicrobials. In an established corneal infection, HB-PNIPAM-van could eliminate enough bacteria from the site of injury and subsequently reduce the overload on the eye's natural defence systems. The dispersion of the biofilm matrix created by the polymer and the lower bacterial concentration in the eye following polymer treatment could improve the success rate of subsequent antimicrobial therapy, using pre-existing agents such as Moxifloxacin.

Whilst it is clear that the effects of polymers and other materials on biofilms is complex, time dependent and species dependent, the data support the hypothesis that HB-PNIPAM with selective ligands at the chain ends forms specific aggregates with the target bacteria, and that these aggregates disrupt the normal formation of biofilms. The aggregates are large amphiphilic structures and their formation appears in this case to promote the dispersion of the biofilm as the bacteria preferentially attach to the polymer rather than the extracellular macromolecules of the biofilm or the underlying surface.

## Experimental

### Materials

*N*-Isopropylacrylamide, NIPAM (97%), *N*-hydroxysuccinimide, NHS (98%), dicyclohexyl carbodiimide, DCC (98% purity), azobiscyanovaleric acid, ACVA (98%), and vancomycin hydrochloride hydrate were obtained from Sigma Aldrich. 4-Vinylbenzylpyrrole carbodithioate (**1**) was synthesised and purified according to the previously reported method.<sup>30</sup> Dioxane (Analar grade), diethyl ether (anhydrous), dimethyl formamide (Analar grade), ethanol (Analar grade), acetone (Analar grade) and hydrochloric acid (35% wt/wt) were obtained from VWR Ltd.

### Highly-branched polymer (HB-PNIPAM)

NIPAM (20 g, 0.17 moles), **1** (1.84 g, 0.0071 moles) and ACVA (1.98 g, 0.0071 moles) were dissolved in 140 ml of 1,4-dioxane.

The solution was degassed and the polymerization conducted under nitrogen at 60 °C for 48 hours. The polymers were purified by precipitation (twice) in diethyl ether. Sample yield 23.1 g, monomer conversion = 97%. The polymer was then dissolved in ethanol and the lower molar mass fraction was removed using ultra-filtration through a 10 000 g mol<sup>-1</sup> molar mass cut off membrane. <sup>1</sup>H NMR (400 MHz, DMSO) (ppm): δ 0.9–1.1 (6H, s, -N(CH<sub>3</sub>)<sub>2</sub>), δ 1.3–1.7 (2H, br m, -CH<sub>2</sub>-CH-Ar-), δ 1.8–2.2 (2H, br m, -CH<sub>2</sub>-CH-CO-NH-) and (1H, br m, CH<sub>2</sub>-CH-CONH-), δ 3.3 (H<sub>2</sub>O-polymer bound), δ 3.9 (1H, br s, (CH<sub>3</sub>)<sub>2</sub>CH-), δ 6.4 (H<sub>2</sub>, br s, *N*-pyrrole-H), δ 6.6–7.6 (br m, -Ar-), δ 7.7 (2H, br s, *N*-pyrrole-H), δ 12.2 (br m COOH). FTIR peak from COOH at 1713 cm<sup>-1</sup>. The polymer molar mass moments after ultra-filtration *via* methanol size exclusion chromatography were *M*<sub>n</sub> 1937.2 kDa, *M*<sub>w</sub> 2269.9 kDa, *M*<sub>z</sub> 2698.2 kDa, LCST (deionised H<sub>2</sub>O) 18.6 °C.

### Polymer chain end modification

The chain ends of the highly branched polymers were converted to carboxylic acid by means of 3 additions of ACVA (20 fold molar excess relative to RAFT agent in the initial polymerisation feed). HB-PNIPAM (22 g) was dissolved in DMF (150 ml). ACVA (19 g, 0.068 moles) was added 3 times after 24 hours intervals. The solution was maintained at 65 °C under a nitrogen atmosphere. The polymer was precipitated into diethyl ether. The solid was dissolved in ethanol and concentrated by ultra-filtration and then rotary evaporated to remove the solvent. 17.7 g of derivatised polymer was obtained. FTIR COOH 1713 cm<sup>-1</sup>. LCST 19.3 °C. The carboxylic acid groups were converted to succinimide by reaction of carboxylic acid chain ends with *N*-hydroxysuccinimide. Highly branched polymer with carboxylic acid chain ends (17.7 g) was dissolved in DMF (150 ml). *N*-Hydroxy succinimide (3.03 g, 0.027 moles) and dicyclohexyl carbodiimide (5.5 g, 0.027 moles) were added and the solution stirred overnight. The mixture was filtered and the polymer precipitated into diethyl ether. The solid was dissolved in ethanol and concentrated by ultra-filtration (10 000 g mol<sup>-1</sup> molar mass cut off membrane) and then rotary evaporated to give 11.8 g of polymer, 67% yield. FTIR (succinimide) 1741 cm<sup>-1</sup>, 1783 cm<sup>-1</sup>. LCST 19.7 °C. Succinimide derivatized polymer (3 g) was dissolved in water (150 ml) over ice. A solution of vancomycin (144 mg, 9.7 × 10<sup>-5</sup> moles) in phosphate buffered saline pH 9.5 (5 ml) was added. The solution was stirred for 3 days at room temperature and purified by ultrafiltration and then freeze dried. FTIR (ESI, Table S1†) shows no identified succinimide or COOH peaks. *M*<sub>n</sub> 4402 kDa, *M*<sub>w</sub> 5439 kDa, *M*<sub>z</sub> 6380.6 kDa, *R*<sub>H</sub> (DOSY, D<sub>2</sub>O) *R*<sub>hn</sub> 8.22, *R*<sub>hw</sub> 8.24, *R*<sub>hz</sub> 8.26 nm. LCST (deionised H<sub>2</sub>O) 32.5 °C.

### Polymer characterisation

All <sup>1</sup>H NMR spectra (ESI, Table S2†) were measured and recorded on a Bruker AC400 which was operated at with D<sub>2</sub>O as the solvent. FTIR measurements were carried out on a Thermo Scientific Nicolet iS10 FTIR Spectrometer. Solid samples were dried in a vacuum oven overnight before use.



Polymer molar mass averages were obtained by size exclusion chromatography using Agilent Polargel columns with methanol as the eluent, using previously published methodologies.<sup>31</sup> This used 3 × Agilent Polargel columns connected to an Agilent 1260 Infinity system with a refractive index, ultraviolet light and viscometric detector, and was calibrated using linear polyNIPAM standards with a methanol eluent at 1 ml min<sup>-1</sup> flow rate. Polymer hydrodynamic radii ( $R_H$ ) were calculated using diffusion ordered spectroscopy (DOSY) NMR in D<sub>2</sub>O at 298 K. Differential Scanning Calorimetry (DSC) was carried out using a TA Instruments MicroDSC in deionised water (1 mg ml<sup>-1</sup>) polymer solution in the range 2 to 60 °C at heating rate of 1 °C min<sup>-1</sup>. Raw data (NMR, FTIR, GPC) are contained in the supplementary material (Fig. S1–S3, Tables S1 and S2†). Polymer samples were stored as a dry powder at –18 °C.

### Bacterial culture

Four strains of *S. aureus* were employed; a reference strain NCTC 8325-4, strain NCTC 6571, strain SH1000-GFP (provided by the Foster lab, University of Sheffield) and strain S-235, a local clinical isolate. In addition *P. aeruginosa* strain SOM-1, a local clinical isolate was used. All strains were cultured in brain heart infusion (BHI) broth (Oxoid, UK) at 37 °C overnight and stored at 4 °C on BHI agar (Sigma-Aldrich, UK). The number of bacterial cells in an overnight culture was enumerated by microscopic counting and diluted to the concentrations required for each experiment.

### Electron microscopy analysis of HB-PNIPAM-van and bacteria binding

Overnight bacterial cultures of *S. aureus* S-235 were diluted with H<sub>2</sub>O to concentrations of 1 × 10<sup>8</sup> CFU ml<sup>-1</sup>. Afterwards, 10 µl of each sample was pipetted on to a cylindrical glass slide and left to stand for 2 hours at room temperature to facilitate attachment. If required, 100 µl of 0.5 mg ml<sup>-1</sup> polymer solution was added to the bacterial sample and left to stand for 4 hours at room temperature before aspiration. Bacteria were fixed using 2.5% glutaraldehyde (GA) (Sigma Aldrich, Cat no. G5882) for 20 minutes. Following aspiration of the GA, samples were washed twice with 100 µl of H<sub>2</sub>O and then dehydrated *via* a graded 100 µl ethanol series (10, 30, 50, 70, 90, 100% ethanol, 10 minutes each) before re-aspiration. Samples were then sputter coated in gold (4 nm) under a 10 mA current for 1 minute and imaged under low vacuum (pressure of 0.59–0.63 Torr) using a scanning electron microscope (Quanta 400 FEI).

### Quantification of bacteria binding to HB-PNIPAM-van

Monoclonal mouse anti-vancomycin antibody (M997129; Abcam, UK) (100 µl per well) was diluted in coating buffer (sodium bicarbonate, 0.035 M, sodium carbonate, 0.015 M and sodium azide, 0.003 M, adjusted to pH 9.6) at a ratio of 1 : 500 in 96-well ELISA microplates and incubated at 4 °C overnight. The plates were then washed 4 times with 200 µl PBS-Tween (1 µl Tween 20 per 200 ml of PBS) and HB-PNIPAM-van (5 mg ml<sup>-1</sup> in PBS) was added to some wells while PBS was

added to others to act as a control. The plates were incubated at RT overnight, washed 4 times with 200 µl of PBS and 100 µl per well of bacterial suspension was added and incubated at room temperature (RT) overnight. *S. aureus* S-235 or *P. aeruginosa* suspensions were prepared at 7 × 10<sup>8</sup> cells per ml in PBS.

After removal of any unattached bacteria by washing 4 times in PBS, attached bacteria were dislodged by thoroughly scraping and vigorously pipetting 100 µl of PBS in each well. Serial dilutions were then made and viable counting performed following spotting (10 µl) of each dilution onto BHI agar and incubation at 37 °C overnight.

An alternative method was also employed in which an overnight culture of bacteria was diluted to 7 × 10<sup>8</sup> bacteria per ml, washed twice in PBS and re-suspended in a solution of FilmTracer™ FM@ 1–43 Green Biofilm Cell Stain (Invitrogen, UK) prepared according to manufacturer's instructions for 20 min at RT. After washing thoroughly in PBS 100 µl of the stained bacterial suspension was added to each coated well (as above) the plates incubated at RT overnight. Plates were washed 4 times with PBS to remove unattached bacteria and residual fluorescence in the wells was measured using a plate-reader (Infinite M200, Tecan, UK) operated by Magellan software (excitation/emission: 472/580 nm).

### The effect of HB-PNIPAM-van on bacterial attachment

An overnight culture of *S. aureus* S-235 was diluted to 10<sup>9</sup> bacteria per ml, washed twice and resuspended in PBS. Then, in fresh Eppendorf tubes, the bacterial suspension was mixed with HB-PNIPAM-van (5 mg ml<sup>-1</sup>) or PBS at a final concentration of 5 × 10<sup>8</sup> cells per ml. The tubes were incubated for 4 hours at 37 °C to encourage HB-PNIPAM-van and bacteria binding. Afterwards, the PBS and HB-PNIPAM-van-*S. aureus* mixtures or the PBS-bacteria controls were added to 96-well microplates and incubated for 2 hours at 37 °C to initiate attachment. Then, the plate was washed 3 times with PBS and the samples stained with SYTO® 9 from LIVE/DEAD™ BacLight™ bacterial viability kit (Invitrogen, UK), (prepared according to manufactures instructions). After washing to remove any residual stain, fluorescence was measured using a Tecan plate reader (excitation/emission: 488/520 nm). Microscopic images were also acquired using the Zeiss Axiovert 200 M inverted fluorescence microscope and the AxioVision software.

### The effect of HB-PNIPAM-van on biofilm formation

Overnight cultures of *S. aureus* S-235 and *S. aureus* NCTC 8325-4 were diluted and added to fresh BHI in a 24-well microplate at a final concentration of 5 × 10<sup>8</sup> bacteria per ml. HB-PNIPAM-van solution (500 µg ml<sup>-1</sup> in PBS) was added to wells while PBS alone was added to polymer-free wells as controls. Biofilms were formed in at 37 °C for 24 hours with gentle shaking (35 rpm), after which wells were washed with PBS and stained with 0.1% (w/v) crystal violet solution for 20 min. The plate was washed thoroughly with water and 200 µl of 95% ethanol was added for 20 min to release the stain from the biofilm bacteria. The absorbance of the



resultant alcohol solution was measured at 595 nm using the plate-reader mentioned previously.

### The effect of HB-PNIPAM-van on biofilm cell growth and biofilm structure

To examine the effects of HB-PNIPAM-van on growth of attached cells and biofilm appearance, *S. aureus* S-235 biofilms were formed as described above. HB-PNIPAM-van ( $5 \text{ mg ml}^{-1}$ ) in PBS was added to the microplate wells and incubation continued for a further 24 hours at  $37^\circ\text{C}$  without shaking. Viable counts from wells were obtained after washing, scraping, serial dilution and plating on BHI agar as described above. The metabolic activity of biofilm cells was assessed using the cell proliferation kit II (XTT) (Roche). Briefly, to *S. aureus* S235 biofilms  $100 \mu\text{l}$  of XTT solution was added (prepared according to manufacturer's instructions), the plates were covered in foil and incubated at  $37^\circ\text{C}$  for 30 min. Following incubation, the XTT solution was transferred into a fresh plate and absorbance readings were recorded at 450 nm with a reference wavelength of 690 nm.

The effects of HB-PNIPAM-van on biofilm structure were examined by fluorescence microscopy and scanning electron microscopy (SEM). For fluorescence microscopy, 24 h *S. aureus* S235 biofilms were grown in 96-well plates as above and stained with  $5 \mu\text{g ml}^{-1}$  of wheat germ agglutinin (WGA) (Texas Red® - X conjugate, Thermo Fisher Scientific, UK) for 15 minutes at  $37^\circ\text{C}$ . In parallel some biofilms were viewed by phase contrast microscopy and this plus the fluorescence images were collected using Zeiss Axiovert 200 M inverted fluorescence microscope and AxioVision software. For scanning electron microscopy *S. aureus* S235, 24 h biofilms were grown in BHI on circular 13 mm diameter cover slips and treated with PBS or HB-PNIPAM-van for 24 hours. Biofilms were then fixed in 3% glutaraldehyde, 0.1 M sodium cacodylate (pH 7.2) and stained, firstly with 0.15% Alcian blue and then with 2% osmium tetroxide in 0.1 M sodium cacodylate (pH 7.2) according to the method of Howlin *et al.* (2015).<sup>32</sup> Finally, samples were critically point dried and sputter coated with gold (Edwards S150B). Images were acquired under full vacuum using a Philips XL-20 scanning electron microscope.

### Corneal infection model

*Ex vivo* corneas were obtained from wild brown rabbits (Blackface Meat Company, Dumfries, Scotland) and their excision, decontamination and infection procedures were performed according to the protocol described by Pinnock *et al.*, (2016).<sup>28</sup> After the development of infection, HB-PNIPAM-van was made up in antibiotic-free Dulbecco's modified eagle's medium (DMEM) to  $5 \text{ mg ml}^{-1}$  and  $100 \mu\text{l}$  of this or PBS (control) was added to the corneas and incubated for 4 hours at  $37^\circ\text{C}$ . Afterwards, the corneas were homogenised and numbers of bacteria were measured by viable counting as previously described.<sup>28</sup> Three corneas were used for each condition per experiment and the experiment was repeated 3 times.

In experiments involving confocal microscopy, corneas were infected with GFP-labelled *S. aureus* SH1000 according to the

procedures described above. After treatment with PBS or HB-PNIPAM-van, corneas were washed twice with PBS and attached to the bottom of a small petri dish (35 mm in diameter) using a tissue adhesive glue (Vetbond™, 3 M Science). Then, the petri dishes were filled with approximately 4 ml of PBS and the corneas were analysed using a Zeiss LSM510 NLO microscope, running AIM software and a Zeiss  $63\times/1.0$  water immersion lens. During preliminary studies, it was discovered that the cornea exhibited some auto-fluorescence at the GFP emission wavelength (Fig. 7), however this was of low intensity and did not prevent imaging of the bacteria. The raw images are shown in ESI, Fig. S4.† The confocal images were processed using ImageJ where the brightness of both the auto-fluorescence and bacterial fluorescence was artificially enhanced for illustration purposes as this enabled visualisation of the bacteria on the corneal surface. There were 2 corneas for each condition and the experiment was repeated twice.

## Conclusions

HB-PNIPAM-van altered the biofilm structure on a surface, inhibited bacterial cell attachment and reduced the bacterial load in a simulated infection of the cornea. These findings suggest that HB-PNIPAM-van offers a new approach to limiting the development of corneal infections and maybe a useful adjunct to antimicrobial treatment.

## Conflicts of interest

There are no conflicts to declare

## Acknowledgements

The authors wish to thank, Jason Heath, Colin Gray and Chris J. Hill for technical support. This work was supported by the Medical Research Council and the Department of Biotechnology, India under grant number, MR/N50188/2.

## References

- 1 S. McCarty, E. M. Jones, S. Finnegan, E. Woods, C. A. Cochrane and S. L. Percival, *Chapter Eighteen - Wound Infection and Biofilms. In Biofilms in Infection Prevention and Control*, Academic Press, Boston, 2014, pp. 339–358.
- 2 M. E. Davey and G. A. O'Toole, Microbial biofilms: from ecology to molecular genetics, *Microbiol. Mol. Biol. Rev.*, 2000, **64**(4), 847–867.
- 3 S. S. Branda, S. Vik, L. Friedman and R. Kolter, Biofilms: the matrix revisited, *Trends Microbiol.*, 2005, **13**(1), 20–26.
- 4 P. D. Fey, Modality of bacterial growth presents unique targets: how do we treat biofilm-mediated infections, *Curr. Opin. Microbiol.*, 2010, **13**(5), 610–615.





- 5 K. I. M. Lewis, Minireview: Riddle of Biofilm Resistance, *Antimicrob. Agents Chemother.*, 2001, **45**(4), 999–1007.
- 6 B. R. Levin and D. E. Rozen, Non-inherited antibiotic resistance, *Nat. Rev. Microbiol.*, 2006, **4**(7), 556–562.
- 7 N. Doroshenko, B. S. Tseng, R. P. Howlin, J. Deacon, J. A. Wharton, P. J. Thurner, B. F. Gilmore, M. R. Parsek and P. Stoodley, Extracellular DNA impedes the transport of vancomycin in *Staphylococcus epidermidis* biofilms preexposed to subinhibitory concentrations of vancomycin, *Antimicrob. Agents Chemother.*, 2014, **58**(12), 7273–7282.
- 8 N. Barraud, D. J. Hassett, S.-H. Hwang, S. A. Rice, S. Kjelleberg and J. S. Webb, Involvement of nitric oxide in biofilm dispersal of *Pseudomonas aeruginosa*, *J. Bacteriol.*, 2006, **188**(21), 7344–7353.
- 9 I. Kolodkin-Gal, D. Romero, S. Cao and J. Clardy, D-amino acids trigger biofilm disassembly, *Science*, 2010, **328**(5978), 627–629.
- 10 B. Boles and A. Horswill, *Staphylococcal*, biofilm disassembly, *Trends Microbiol.*, 2011, **19**(9), 449–455.
- 11 I. M. Banat, M. A. D. De Rienzo and G. A. Quinn, Microbial biofilms: biosurfactants as antibiofilm agents, *Appl. Microbiol. Biotechnol.*, 2014, **98**(24), 9915–9929.
- 12 O. Schreiberová, P. Hedbávná, A. Čejková, V. Jirků and J. Masák, Effect of surfactants on the biofilm of *Rhodococcus erythropolis*, a potent degrader of aromatic pollutants, *New Biotechnol.*, 2012, **30**(1), 62–68.
- 13 J. Luo, W. Lv, Y. Deng and Y. Sun, Cellulose-Ethylenediaminetetraacetic Acid Conjugates Protect Mammalian Cells from Bacterial Cells, *Biomacromolecules*, 2013, **14**(4), 1054–1062.
- 14 S. S. E Silva, J. W. P. Carvalho, C. P. Aires and M. Nitschke, Disruption of *Staphylococcus aureus* biofilms using rhamnolipid biosurfactants, *J. Dairy Sci.*, 2017, **100**(10), 7864–7873.
- 15 P. S. Yavvari, S. Gupta, D. Arora, V. K. Nandicoori, A. Srivastava and A. Bajaj, Clathrin-Independent Killing of Intracellular Mycobacteria and Biofilm Disruptions Using Synthetic Antimicrobial Polymers, *Biomacromolecules*, 2017, **18**(7), 2024–2033.
- 16 D. S. Uppu, S. Samaddar, C. Ghosh, K. Paramanandham, B. R. Shome and J. Haldar, Amide side chain amphiphilic polymers disrupt surface established bacterial bio-films and protect mice from chronic *Acinetobacter baumannii* infection, *Biomaterials*, 2016, **74**, 131–143.
- 17 J. S. Khara, S. Obuobi, Y. Wang, M. S. Hamilton, B. D. Robertson, S. M. Newton, Y. Y. Yang, P. R. Langford and P. L. R. Ee, Disruption of drug-resistant biofilms using de novo designed short  $\alpha$ -helical antimicrobial peptides with idealized facial amphiphilicity, *Acta Biomater.*, 2017, **57**(Supplement C), 103–114.
- 18 J. Coronel-León, A. M. Marqués, J. Bastida and A. Manresa, Optimizing the production of the biosurfactant lichenysin and its application in biofilm control, *J. Appl. Microbiol.*, 2016, **120**(1), 99–111.
- 19 J. Shepherd, P. Sarker, K. Swindells, C. W. I. Douglas, S. MacNeil, L. Swanson and S. Rimmer, Binding bacteria to highly branched poly(*N*-isopropyl acrylamide) modified with vancomycin induces the coil-to-globule transition, *J. Am. Chem. Soc.*, 2010, **132**(6), 1736–1737.
- 20 J. Shepherd, P. Sarker, S. Rimmer, L. Swanson, S. MacNeil and I. Douglas, Hyperbranched poly(NIPAM) polymers modified with antibiotics for the reduction of bacterial burden in infected human tissue engineered skin, *Biomaterials*, 2011, **32**(1), 258–267.
- 21 P. Sarker, K. Swindells, C. W. I. Douglas, S. MacNeil, S. Rimmer and L. Swanson, Förster resonance energy transfer confirms the bacterial-induced conformational transition in highly-branched poly(*N*-isopropyl acrylamide with vancomycin end groups on binding to *Staphylococcus aureus*, *Soft Matter*, 2014, **10**(31), 5824–5835.
- 22 P. Teratanatorn, R. Hoskins, T. Swift, C. W. I. Douglas, J. Shepherd and S. Rimmer, Binding of bacteria to poly(*N*-isopropylacrylamide) modified with vancomycin: Comparison of behavior of linear and highly branched polymers, *Biomacromolecules*, 2017, **18**(9), 2887–2899.
- 23 P. Sarker, J. Shepherd, K. Swindells, I. Douglas, S. MacNeil, L. Swanson and S. Rimmer, Highly branched polymers with polymyxin end groups responsive to *Pseudomonas aeruginosa*, *Biomacromolecules*, 2011, **12**(1), 1–5.
- 24 S. Resnikoff, D. Pascolini, D. Etya'ale, I. Kocur, R. Pararajasegaram, G. P. Pokharel and S. P. Mariotti, Global data on visual impairment in the year 2002, *Bull. W. H. O.*, 2004, **82**(11), 844–851.
- 25 M. Green, A. Apel and F. Stapleton, Risk Factors and Causative Organisms in Microbial Keratitis, *Cornea*, 2008, **27**(1), 22–27.
- 26 M. J. Elder, F. Stapleton, E. Evans and J. K. Dart, Biofilm-related infections in Ophthalmology, *Eye*, 1995, **9**, 102–109.
- 27 K. K. Jefferson, What drives bacteria to produce a biofilm, *FEMS Microbiol. Lett.*, 2004, **236**(2), 163–173.
- 28 A. Pinnock, N. Shivshetty, S. Roy, S. Rimmer, I. Douglas, S. MacNeil and P. Garg, Ex vivo rabbit and human corneas as models for bacterial and fungal keratitis, *Graefes Arch. Exp. Ophthalmol.*, 2016, **255**, 333–342.
- 29 I. A. D. Lessard and C. T. Walsh, VanX, a bacterial D-alanyl-D-alanine dipeptidase: Resistance, immunity, or survival function, *PNAS*, 1999, **96**, 11028–11032.
- 30 S. Hopkins, S. R. Carter, J. W. Haycock, N. J. Fullwood, S. MacNeil and S. Rimmer, Sub-micron poly(*N*-isopropylacrylamide) particles as temperature responsive vehicles for the detachment and delivery of human cells, *Soft Matter*, 2009, **5**, 4928–4937.
- 31 T. Swift, R. Hoskins, R. Telford, R. Plenderleith, D. Pownall and S. Rimmer, Analysis using size exclusion chromatography of poly(*N*-isopropylacrylamide) using methanol as an eluent, *J. Chromatogr. A*, 2017, **1508**, 16–23.
- 32 R. P. Howlin, M. J. Brayford, J. S. Webb, J. J. Cooper, S. S. Aiken and P. Stoodley, Antibiotic-loaded synthetic calcium sulfate beads for prevention of bacterial colonization and biofilm formation in periprosthetic infections, *Antimicrob. Agents Chemother.*, 2015, **59**(1), 111–120.

